Tag: Eyecyte RPE
Eyestem raises funds to advance Eyecyte-RPE™ through phase 2 clinical trial...
The capital will enable completion of the ongoing Phase 2 clinical trial in India and support preparations for filing an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA)
Eyestem completes first set of patient injections for its pioneering Dry...
Eyecyte-RPE™ is a patented suspension of retinal pigment epithelium cells aimed at combating geographic atrophy arising from Dry AMD
Endiya Partners invest in cell therapy company, Eyestem
The company is poised to become one of the first companies in the world to develop a treatment for Dry AMD (Age-related Macular Degeneration), the largest cause of incurable blindness that affects nearly 170 million people worldwide...........................